The Manufacturers Life Insurance Company Has $9.34 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

The Manufacturers Life Insurance Company lessened its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 16.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 74,778 shares of the biotechnology company's stock after selling 14,747 shares during the quarter. The Manufacturers Life Insurance Company owned 0.08% of Sarepta Therapeutics worth $9,339,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of SRPT. Innealta Capital LLC purchased a new position in Sarepta Therapeutics in the second quarter valued at about $31,000. Huntington National Bank boosted its holdings in Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 175 shares during the last quarter. Nkcfo LLC purchased a new position in Sarepta Therapeutics in the second quarter valued at about $43,000. Riggs Asset Managment Co. Inc. boosted its holdings in Sarepta Therapeutics by 33.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 75 shares during the last quarter. Finally, UMB Bank n.a. boosted its holdings in Sarepta Therapeutics by 105.9% in the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 197 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on SRPT. StockNews.com cut Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Barclays cut their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. Citigroup cut their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a "neutral" rating on the stock in a research note on Thursday, August 8th. UBS Group upped their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a "buy" rating in a research note on Tuesday, September 17th. Finally, Raymond James restated an "outperform" rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. One analyst has rated the stock with a sell rating, two have given a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of "Moderate Buy" and an average price target of $175.55.

Sarepta Therapeutics Stock Up 0.4 %

NASDAQ SRPT traded up $0.52 during trading on Wednesday, hitting $126.53. 489,624 shares of the company traded hands, compared to its average volume of 1,241,923. Sarepta Therapeutics, Inc. has a 12 month low of $83.97 and a 12 month high of $173.25. The business has a fifty day simple moving average of $122.57 and a 200 day simple moving average of $131.40. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $12.09 billion, a P/E ratio of 100.81 and a beta of 0.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.